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Introduction
Fluid resuscitation for critically-ill patients has been a staple of treatment since the
induction of the first crystalloid in 1830 for treatment of cholera.1 Colloid solutions, the first
being gelatins, were later created in the 1930s for shock treatment. Albumin was fractionated
from whole blood and extensively used during World War II.2 It was not until after World War II
the pathophysiology behind these two solutions was well studied and debated for effectiveness.
There has been a heated debate on how to appropriately manage fluid dynamics in
critically-ill patients, in particular using crystalloids vs colloid fluids. Using crystalloids to
replenish volume within the vascular system through hydrostatic pressure leads to fluid
accumulation in the extracellular space. Administration of fluids in a healthy individual has
shown that crystalloids expand the intravascular space by 20% of infused volume; however,
under physiological stress efficacy can increase up to 60%.3
The average adult is roughly comprised of 50-60% water that embodies the intracellular
and extracellular space.1 Extracellular space is further broken into the interstitial, intravascular,
and transcellular spaces. Because crystalloids are small molecules, most providers are concerned
about the interstitial edema associated with revascularization. Critical illness causes
inflammatory states that leads to endothelial dysfunction associated with interstitial edema. Since
one significant downside of crystalloid administration is fluids crossing the permeable
membrane, colloids can complete resuscitation without changing oncotic pressure and avoiding
edema while increasing intravascular expansion. Due to the increased molecular weight and
larger molecules associated with colloids, it is relatively impermeable to an intact capillary
membrane.2
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Now that there are over sixty years of research on the topic, is there a consensus on what
is more successful for fluid resuscitation? The goal of this literature review is to consider when
colloid use is appropriate, and if so, is there any significant benefit that cannot be accomplished
with crystalloid therapy alone.
Hemodynamics
One area of discussion is whether crystalloids achieves a better hemodynamic response
when compared to colloids. A study by Nicholas et al. compared 220 patients with a pulmonary
artery catheterization based on the CRISTAL trail evaluating demographics, heart rate, stroke
volume, blood pressure, and central venous pressure (CVP) measured by pulmonary artery
catheter (PAC). Out of the 220 patients studied 103 received crystalloids while 117 were
administered colloids. All patients were administered no more than 30ml/kg for resuscitation.
Overall, administration of colloids was associated with lower heart rates and volume
administration when resuscitating patients 3500 vs. 2500 ml when comparing hydroxy starches
to normal saline. To achieve similar treatment goals, crystalloids should be administered using
20-50% more volume than colloids.
The SAFE study evaluated the use of 4% albumin when compared to 9% saline and was
found to show statistical significance with lower heart rate on the first day of treatment.4
Alternative studies such as the Albumin Italian Outcome Sepsis (ALBIOS) and Crystalloid
Versus Hydroxyethyl Starches Trial (CHEST) found decreased heart rate, lower use of
vasopressor therapy, and higher CVP respectively when comparing starches, albumin, and saline.
Some argue that by retaining a negative fluid balance, respiratory distress syndrome can
be avoided in the septic patient. Negative fluid balance is accomplished when colloids remain in
the intravascular space from oncotic pressure. In the sepsis subgroup, the first six hours it was
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noted that approximately 69% of patients during the study reach mean arterial pressure and urine
output goals for resuscitation. This is in contrast to the colloid group, where 66% of patients
reached the same outcomes.4 The conclusion of the study was there is zero difference between
the management of patients with sepsis for achieving hemodynamic goals set by the 6-hour
campaign of surviving sepsis. There was no difference in any other hemodynamic endpoint other
than the HR, and rate pressure product.4
Complications
Colloids, particularly starches, have an extensive complication profile including kidney
injury, which requires renal replacement treatment. The CHEST trial compared Hydroxyethyl
starch (HES) 6% vs. 0.9% saline and found renal replacement therapy to be significantly
increased.5 The Scandinavian Starch Study and Efficacy of Volume Substitution and Insulin
Therapy in Severe Sepsis Study found that use of starches have an increased association of acute
kidney injury (AKI) when compared to crystalloids.6-8 Hydroxyethyl starches can accumulate in
the skin, liver, and kidney causing Hydrops Lysosomalis Generalisatus which is associated with
pruritus, coagulopathy, AKI, and potential hyperbilirubinemia.5
In 2012, a prospective open-label pilot study was accomplished in Australia that
restricted use of fluids to specialist approval only under standard fluid therapy with a 6-month
phase-out period. Since implementation, there has been a significant decrease in the incidence of
AKI and renal replacement treatment,9 though it has yet to be proven on a large scale. New
generation 6% HES with a lower molecular weight were produced for an improved safety
profile, but there is increased mortality based on systematic reviews.
High molecular weight HES and medium molecular weight can cause adverse effects on
coagulation. Colloids can be challenging to break down, which impairs coagulation through an

3

accumulation of large molecules reducing factor VIII and Von Willebrand Factor complex.10
Ultimately, this accumulation of molecules can lead to a hemorrhagic complication. Other side
effects are increased plasma viscosity and erythrocyte aggregation. Starches are also linked with
a potential need for blood transfusion.9 However, coagulation complications are not seen in the
low molecular weight starches.
Another side effect that has commonly been associated with colloids is potential for a
severe allergic reaction upon infusion of dextrans, starches, gelatins, or albumin. Little to no
difference between rates of allergic reactions was found between crystalloids and colloids when
compared.9 Itching and rashes appeared to be connected to the use of colloids. A retrospective
study from the SAFE trial linked albumin to increasing intercranial pressure with fluid
resuscitation.11
Use of normal saline (0.9%) has concerns due to hyperchloremic metabolic acidosis
induced from large volumes of administration requiring treatment with bicarb. Volunteer studies
have shown the development of AKI, and reduction in glomerular filtration from
vasoconstriction due to eicosanoid release in renal tissue.5,12 Acidosis can be viewed as poor
tissue perfusion, cardiac function, and may prompt application of additional fluid boluses
exacerbating the acidosis. Saline has also been linked to the use of renal replacement therapy,
poor outcomes with use in ICU patients, sepsis, and complications with patients who undergo
surgery.13-14
Outcomes
In 1998 a systematic review was completed by the Cochrane Injury Group Albumin
Reviewers to compare the effects of albumin on a patient with hypovolemia: burns, and hypoalbuminemia on mortality. It was found that albumin had a 6% increase in mortality, which
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created a drastic change in patient management in the UK.2 Since Australia and New Zealand
were widely using albumin at this time, a larger blind study named the SAFE study demonstrated
there was no associated increase in mortality with the use of albumin when compared to 0.9%
saline at 28 days.2 The findings refuted the initial findings from the Cochrane study. Two years
later, an increase in mortality was observed in patients who had experienced a severe traumatic
brain injury with colloids compared to saline (34.4% vs 17.4%).11 Currently, the increase in
mortality is being attributed to the development of intracranial hypertension during the first
seven days due to extravasation of albumin across the blood-brain barrier.2 In the same study,
there was found to be a significant reduction in adjusted risk of death at 28 days for those who
received albumin therapy. The ALBIOS trial also suggested a reduction in mortality with
patients that received albumin with septic shock.
Mortality rate over 90 days was observed to be lower in the colloid population (30.7%)
when compared to the crystalloid (34.2%) in the CRISTAL trial.4 It has been explained to be
exploratory as it may have some explanation toward the long-term effects of colloid
resuscitation. The colloid group was observed to experience more days alive without mechanical
ventilation required. It was also observed that survival without vasopressor therapy was
increased in the colloid population at seven days and 28 days respectively.
Additional studies have had similar findings. A meta-analysis concluded the use of
albumin-based therapy for individuals with severe sepsis or septic shock improved mortality rate
over 90 days.15 There was also a slight improvement in outcome when compared to normal
saline although it was not statistically significant. More extensive studies comparing starches,
dextrans, gelatins, or albumin looked at 90-day mortality rates in trauma, burns, and sepsis found
little to no difference without limiting research to severe sepsis or septic shock.9 Trauma patients
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have been associated with an increased in mortality with the used of colloid therapy when
compared to crystalloid resuscitation.1
In surgery, there have been multiple studies on perioperative fluid management. A large
multi-center study found no difference between mortality, although colloids under individualized
goal-directed therapy (GDT) received less major complications.3 Colloid GDT did not have the
same results within the "fit" (anaerobic threshold >11 ml O2 kg-1min-1) population when
compared to the "unfit" (anaerobic threshold 8.9-10.9 ml O2 kg-1min-1) who underwent
significant colorectal surgery.2 Patients who were fit were found to have an extended hospital
stay when compared to the controls, while unfit patients had no difference.
Conclusion
Gelatins have not received the same extensive research attention that has been given to
albumin and starches.4 Studies that focus strictly on hemodynamics account for 10% of the
patients who were enrolled in the CRYSTAL trial, one of the largest studies to date for
comparison on fluid therapy. There has also been an advancement in monitoring hemodynamics
without the use of a PAC thus limiting comparison between trials. Large extensive studies on
each type of patient have not been completed, so sample sizes for severe septic patients are
small. Future research should be focused on patient and condition directed therapies since not
every fluid will fit every situation. This will help determine what type of fluid is most useful for
which type of patient.
It is hard to justify the cost of using colloid resuscitation without strong evidence of its
efficacy when compared to crystalloid fluids. Although, there have been reoccurring themes
throughout the literature. There may be a benefit in 90-day mortality with the use of colloid
therapy especially albumin in the patient with septic shock or severe sepsis. Providers that are
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administering the fluid should be well trained on colloid therapy to avoid side effects such as
AKI. In most cases, there is no increased benefit in the use of starches or gelatins when
compared to crystalloids therapy and come with an increased profile for adverse complications.
Patients should continue to receive crystalloid therapy during salvage therapy unless blood
products take priority. Albumin ought to be considered for fluid resuscitation in septic patients as
long as there is not an accompanying traumatic brain injury or trauma. Fluid therapy is quite
complex and there is no clear consensus. By far, the best recommendation is picking a fluid with
the patient’s comorbid conditions in mind and proceeding with goal-directed therapy.
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